%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 18 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R /F4 11 0 R >> /ExtGState << /GS1 16 0 R /GS2 17 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260401032438+00'00') /ModDate (D:20260401032438+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 12 0 R 14 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 5984 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Announces Ocifisertib, a First-in-Class PLK4)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Inhibitor, has Received Orphan Designation from U.S. FDA for)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(the Treatment of Acute Myeloid Leukemia)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(TORONTO & SAN FRANCISCO??\()] TJ ET 0.000 0.000 0.800 rg BT 232.364 669.017 Td /F1 12.0 Tf [(BUSINESS WIRE)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 232.364 666.407 m 327.716 666.407 l S 0.000 0.000 0.000 rg BT 327.716 669.017 Td /F1 12.0 Tf [(\)??Treadwell Therapeutics, a privately held)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(needs in cancer, today announced the U.S. Food and Drug Administration \(FDA\) has granted orphan)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(drug designation to ocifisertib \(CFI-400945\), a first-in-class, investigational PLK4 inhibitor for the)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(treatment of acute myeloid leukemia \(AML\). Ocifisertib is currently being evaluated in a Phase 1b/2)] TJ ET BT 35.000 595.757 Td /F1 12.0 Tf [(study in adults with relapsed/refractory AML following standard of care therapy.)] TJ ET BT 35.000 569.105 Td /F1 12.0 Tf [(Orphan drug designation is granted by the FDA to drugs intended for treatment, prevention or diagnosis)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(designation. Under the FDA??s Orphan Drug Act, orphan drug status provides incentives, grants, tax)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(credits and waiver of certain administrative fees as well as seven years of market exclusivity following)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(marketing authorization.)] TJ ET BT 35.000 483.845 Td /F1 12.0 Tf [(Treadwell also announced today the appointment of Brenda Marczi, as SVP and Head of Regulatory)] TJ ET BT 35.000 469.193 Td /F1 12.0 Tf [(Affairs. Brenda comes to Treadwell with over 30 years of regulatory experience in the pharmaceutical)] TJ ET BT 35.000 454.541 Td /F1 12.0 Tf [(and biotechnology industries. She most recently served as Senior Vice President, Regulatory Affairs at)] TJ ET BT 35.000 439.889 Td /F1 12.0 Tf [(Tracon Pharmaceuticals, Inc., where she oversaw their regulatory function and led all of their strategies)] TJ ET BT 35.000 425.237 Td /F1 12.0 Tf [(and filing activities in the US and UK. Brenda holds a Master of Science in Pharmaceutical Sciences)] TJ ET BT 35.000 410.585 Td /F1 12.0 Tf [(from Rutgers University, a PharmD from the University of Maryland, and an MBA from Wharton,)] TJ ET BT 35.000 395.933 Td /F1 12.0 Tf [(University of Pennsylvania.)] TJ ET BT 35.000 369.281 Td /F1 12.0 Tf [(??The FDA??s decision to grant orphan drug designation, along with the previous FDA Fast Track)] TJ ET BT 35.000 354.629 Td /F1 12.0 Tf [(designation for ocifisertib underscores Treadwell??s dedication to addressing this patient population)] TJ ET BT 35.000 339.977 Td /F1 12.0 Tf [(with few treatment options. Patients with relapsed and/or refractory AML, in particular)] TJ ET BT 489.848 339.977 Td /F4 12.0 Tf [(TP53)] TJ ET BT 518.528 339.977 Td /F1 12.0 Tf [(mutated)] TJ ET BT 35.000 325.325 Td /F1 12.0 Tf [(disease suffer poor overall survival and represents a high unmet clinical need,?)] TJ ET BT 461.852 325.325 Td /F1 12.0 Tf [()] TJ ET BT 465.188 325.325 Td /F1 12.0 Tf [( said Roger Sidhu,)] TJ ET BT 35.000 310.673 Td /F1 12.0 Tf [(M.D., Acting CEO of Treadwell. ??We look forward to advancing ocifisertib in partnership with)] TJ ET BT 35.000 296.021 Td /F1 12.0 Tf [(investigators, regulators, patients and their families for those with limited treatment options in tough to)] TJ ET BT 35.000 281.369 Td /F1 12.0 Tf [(treat AML. In addition, we are thrilled to have Brenda join us to lead Regulatory Affairs at Treadwell.)] TJ ET BT 35.000 266.717 Td /F1 12.0 Tf [(She is a seasoned strategic leader with a broad experience in leading regulatory strategy from early)] TJ ET BT 35.000 252.065 Td /F1 12.0 Tf [(development through approval. Her leadership will be invaluable to Treadwell as we advance ocifisertib)] TJ ET BT 35.000 237.413 Td /F1 12.0 Tf [(into potentially pivotal studies in 2025.?)] TJ ET BT 250.448 237.413 Td /F1 12.0 Tf [()] TJ ET BT 35.000 206.728 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 165.538 Td /F1 12.0 Tf [(Treadwell Therapeutics is a clinical-stage oncology company developing novel medicines to address)] TJ ET BT 35.000 150.886 Td /F1 12.0 Tf [(unmet needs in patients with cancer. The Company??s robust, internally developed clinical pipeline)] TJ ET BT 35.000 136.234 Td /F1 12.0 Tf [(includes CFI-400945 \(PLK4 inhibitor\), CFI-402257 \(TTK/Mps1 inhibitor\) and CFI-402411 \(HPK1)] TJ ET BT 35.000 121.582 Td /F1 12.0 Tf [(inhibitor\). Treadwell also has a broad pre-clinical pipeline with multiple biologic and next generation)] TJ ET BT 35.000 106.930 Td /F1 12.0 Tf [(TCR based autologous cell therapy programs. For more information, please visit)] TJ ET 0.000 0.000 0.800 rg BT 463.820 106.930 Td /F1 12.0 Tf [(www.treadwelltx.com)] TJ ET 463.820 104.320 m 576.500 104.320 l S 0.000 0.000 0.000 rg BT 576.500 106.930 Td /F1 12.0 Tf [(.)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Font /Subtype /Type1 /Name /F4 /BaseFont /Helvetica-Oblique /Encoding /WinAnsiEncoding >> endobj 12 0 obj << /Type /Annot /Subtype /Link /F 28 /A 13 0 R /Border [0 0 0] /H /I /Rect [ 232.3640 666.6861 327.7160 678.8961 ] >> endobj 13 0 obj << /Type /Action /S /URI /URI (https://www.businesswire.com/) >> endobj 14 0 obj << /Type /Annot /Subtype /Link /F 28 /A 15 0 R /Border [0 0 0] /H /I /Rect [ 463.8200 104.5992 576.5000 116.8092 ] >> endobj 15 0 obj << /Type /Action /S /URI /URI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcan01.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.treadwelltx.com%252F%26data%3D04%257C01%257Cm.tusche%2540treadwelltx.com%257C9fada6d2333c422cc9e508da1d9451c2%257C04db3f8aae8b42e388b384cb3a2c34aa%257C0%257C0%257C637854820132066875%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C3000%26sdata%3DwwW9sHtyeKQePfVCHWCu%252F5C56tKDyernS4dxH5H9aVg%253D%26reserved%3D0&esheet=53896205&newsitemid=20240213511904&lan=en-US&anchor=www.treadwelltx.com&index=1&md5=2891f06be7a4ef634c0a07cb63470dbf) >> endobj 16 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 17 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 18 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 20 0 R ] /Contents 19 0 R >> endobj 19 0 obj << /Length 820 >> stream 0.000 0.000 0.000 rg BT 35.000 818.176 Td /F3 14.0 Tf [(Contact)] TJ ET 0.000 0.000 0.800 rg BT 35.000 788.986 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 35.000 786.376 m 137.192 786.376 l S 0.000 0.000 0.000 rg BT 35.000 762.334 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 747.682 Td /F1 12.0 Tf [(February 20, 2024)] TJ ET q 35.000 744.751 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 20 0 obj << /Type /Annot /Subtype /Link /F 28 /A 21 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 786.6546 137.1920 798.8646 ] >> endobj 21 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj xref 0 22 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000355 00000 n 0000000384 00000 n 0000000533 00000 n 0000000662 00000 n 0000006698 00000 n 0000006805 00000 n 0000006914 00000 n 0000007027 00000 n 0000007143 00000 n 0000007277 00000 n 0000007358 00000 n 0000007492 00000 n 0000008172 00000 n 0000008229 00000 n 0000008286 00000 n 0000008410 00000 n 0000009282 00000 n 0000009415 00000 n trailer << /Size 22 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 9492 %%EOF